Please login to the form below

Not currently logged in

Roche to buy cancer data firm Flatiron for $1.9bn

Roche Basel Switzerland

Data provides a wealth of RWE opportunities

Merck/Pfizer’s cancer immunotherapy latecomer hits a snag

Merck KGaABavencio fails a key lung cancer trial

BMS pens massive $3.6bn deal for Nektar cancer immunotherapy

Bristol-Myers Squibb (BMS) buildingNektar’s NKTR-214 to be paired with Opdivo and Yervoy in a host of tumour types

J&J’s Erleada first US drug for non-metastatic prostate cancer

Drug approved by the FDA on the back of data from the SPARTAN study

Another Alzheimer's bust as Merck & Co stops verubecestat study

Merck and Co - US headquartersLate-stage BACE1 failure could be an ominous signal for Eli Lilly/AZ and Biogen/Eisai

Vertex's two-drug cystic fibrosis treatment cleared in US

Vertex PharmaFDA approves Symdeko, which combines Kalydeco and tezacaftor

Boehringer abandons PDE-targeted Alzheimer’s drug

But will keep testing the candidate in schizophrenia

J&J extends its JLABS incubator scheme to Europe

The Belgian site will accommodate up to 30 life science start-ups

Celgene’s triple multiple myeloma therapy clears phase III trial

Celgene buildingThe biotech says the combo hit its OPTIMISMM primary endpoint

clusterAdopting a creative IP approach towards biotech clusters

Why big pharma paradigm needs to change

Featured jobs

Subscribe to our email news alerts


Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

Finding the patient voice
How patients feel and speak about clinical trials...
Six Factors to Consider When Designing Advisory Boards
The good, the bad and the ugly
Tracking the pharmaceutical industry’s 2017 evolution and assessing how things may shape up in 2018 - it’s a trilogy of trends...